Section 4 of 6
Clinical evidence
313 evidence topics · 54 sources
Study summaries
NATiV3
Objective
Primary objectives of Part A and Part B in the ClinicalTrials.gov record
Key secondary and other secondary objectives in the ClinicalTrials.gov record
Main objective in the EU Clinical Trials Information System record
Aim of the trial stated by the company in September 2026
Primary objectives of Part 1 and Part 2 in the original ClinicalTrials.gov record, April 2021, superseded in March 2023
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2021-08-19” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2026-09-29” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-09-30” (opens the source at this quote in a new tab)
“First Posted 2021-04-19” (opens the source at this quote in a new tab)
“Last Update Posted 2026-11-02” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Number of locations in the ClinicalTrials.gov record
EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record
Activation of the first sites in the United States, September 2021
Sites, countries, and regional distribution of randomized participants, December 2023
Initiation, sites in Ukraine and Russia, China participation, and completion of screening and randomization stated in the Form 20-F
Last patient visit of the 72-week treatment period, September 2026
Estimated completion dates in the ClinicalTrials.gov record, January 2023, superseded in March 2023
Study design
Official title and design details in the ClinicalTrials.gov record
Trial phase and transition status in the EU Clinical Trials Information System record
Main cohort, exploratory cohort, and active treatment extension in the company design slide
“Noncirrhotic MASH and F2-F3 fibrosis” (opens the source at this quote in a new tab)
“Screen-failed patients from the main cohort” (opens the source at this quote in a new tab)
“noncirrhotic MASH and F1-F4 fibrosis” (opens the source at this quote in a new tab)
“Stratification by fibrosis stage and diabetic status” (opens the source at this quote in a new tab)
Randomization ratio, stratification factors, and amended design stated by the company
Active treatment extension described as double-blind in the registry records
Extension described as open-label by the company in September 2026
Exploratory cohort of participants histologically not eligible for the main cohort
Central biopsy review process developed with regulatory authorities
January 2023 protocol amendments replacing Part 2 with a separate outcomes trial in compensated cirrhosis
Amended design posted in the ClinicalTrials.gov record, March 2023
Two-part design with a Part 2 clinical outcomes period in about 2,000 participants, January 2021, superseded in January 2023
Part 2 clinical outcome primary measure in the ClinicalTrials.gov record, January 2023, superseded in March 2023
Eligibility criteria
Prescreening criteria in the ClinicalTrials.gov record
Liver-related exclusion criteria in the ClinicalTrials.gov record
Glycemic, obesity-related, cardiovascular, and general exclusion criteria in the ClinicalTrials.gov record
“HbA1c >9% at Screening” (opens the source at this quote in a new tab)
“Diabetes mellitus other than type 2” (opens the source at this quote in a new tab)
“Current treatment with insulin” (opens the source at this quote in a new tab)
“Atrial fibrillation requiring anticoagulation” (opens the source at this quote in a new tab)
Concomitant GLP-1 receptor agonist allowed at a stable dose, company design slide
Exclusion of autoimmune liver or thyroid disease added after a suspected unexpected serious adverse reaction, February 2024
Treatment
Treatment arms and tablets in the ClinicalTrials.gov record
Randomization to two lanifibranor doses or placebo stated by the company
Treatment duration of the main and exploratory cohorts and the extension, company design slide
Active treatment with lanifibranor for all participants during the 48-week extension
Liver monitoring every 6 weeks added for enrolled participants, March 2024
Study outcomes
Rationale for using MASH resolution and fibrosis improvement of at least one stage as the primary endpoint
Primary outcome measure as named and defined in the ClinicalTrials.gov record
Primary endpoint as a composite and the two single histologic endpoints as key secondary endpoints, company wording
“Primary end point:” (opens the source at this quote in a new tab)
“Key secondary end points:” (opens the source at this quote in a new tab)
Single histologic endpoints named key primary or key secondary endpoints in the company's financing terms
Primary outcome measure titled resolution of NASH in the original ClinicalTrials.gov record, April 2021, superseded in October 2021
Composite endpoint carried over from the phase 2b NATIVE trial
Phase 2b effect on the composite endpoint by type 2 diabetes status cited for NATiV3
FDA draft guidance: histologic endpoints reasonably likely to predict clinical benefit for accelerated approval
FDA draft guidance: confirmatory outcome trials underway at submission and the composite clinical endpoint
EMA reflection paper: two composite histologic endpoints required as co-primary endpoints for conditional approval
Regulatory consultation before the trial: accelerated and conditional approval on the 72-week histology analysis
Accelerated approval on histologic endpoints and confirmation in a separate outcomes trial after the January 2023 amendments
Precedent: accelerated approval of resmetirom based on the two single histologic endpoints
Reliability of NASH CRN histologic scoring between readers in a phase 2 trial
“Inter-reader linearly weighted kappas were 0.609, 0.484, 0.328, and 0.517 for steatosis, fibrosis, lobular inflammation, and ballooning, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inter-reader unweighted kappas were 0.400 for the diagnosis of NASH, 0.396 for NASH resolution without worsening fibrosis, and 0.366 for fibrosis improvement without worsening NASH.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Simulations show that the lack of reliability of endpoints and inclusion criteria can drastically reduce study power - from >90% in a well-powered study to as low as 40%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EMA reflection paper: observer variability of the NASH CRN system and centralized reading by at least two histopathologists
Digital versus glass slide reading of NATiV3 screening biopsies, AASLD 2025 poster
Validation of whole slide images against glass slides for steatohepatitis scoring in clinical trials
“The results from this validation study support the conclusion that the WSI IMS platform is equivalent to the glass read in reference to a robust glass GT when used by pathologists to evaluate steatohepatitis trial populations for diagnosis and trial‐based scoring criteria and histologic feature scoring during enrollment and for follow‐up timepoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA statements on noninvasive biomarkers as replacements for liver biopsy
Noninvasive tests in the exploratory cohort
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the ClinicalTrials.gov record
Enrollment targets and participants randomized in the main and exploratory cohorts, April 2025
Statistical power for the sample size calculation and enrollment, company design slide
Participants planned for the histologic analysis supporting the NDA, Form 20-F
Estimated enrollment of 2000 in the ClinicalTrials.gov record, April 2021, superseded in March 2023
Planned histology analysis in about 900 participants, January 2021, superseded in April 2025
Planned exploratory cohort of about 200 participants, December 2023, superseded in April 2025
Description of analysis sets
Analysis periods for the Part B safety analyses in the ClinicalTrials.gov record
Histologic analysis population and exploratory cohort contribution to the safety database, Form 20-F
Results
Participant disposition
Completion of randomization in the main and exploratory cohorts and the drop-out condition, April 2025
Completion of the 72-week treatment period by all participants, September 2026
Participants remaining to complete the 72-week biopsy, October 2025
Randomized participants, screening, and screen failure rate, December 2023
Participants randomized before the voluntary screening pause, February 2024
Treatment duration of participants at the fifth Data Monitoring Committee review, October 2024
Screen failure rate and enrollment delays stated in the Form 20-F
Baseline characteristics
Demographic and metabolic characteristics of the NATiV3 main cohort compared with NATIVE, company slides
| Characteristic | NATiV3 (main cohort) | NATIVE |
|---|---|---|
| Participants | “NATiV3 N=1009” | “NATIVE N=247” |
| Female | “59%” | “58%” |
| Male | “41%” | “42%” |
| Weight (kg), mean (SD) | “97.10”; “(± 23.6)” | “93.30”; “(± 18.8)” |
| BMI class obese (30 or more) | “75%” | “65%” |
| Type 2 diabetes | “55%” | “42%” |
| HOMA-IR, mean (SD) | “9.8”; “(± 10.2)” | “10.1”; “(± 12.7)” |
| HbA1c, mean (SD) | “6.5%”; “(± 1.0)” | “6.0%”; “(± 0.7)” |
| Adiponectin (µg/mL), mean (SD) | “4.6”; “(± 2.7)” | “5.1”; “(± 2.7)” |
“median: NATiV3 = 95kg | NATIVE = 92kg” (opens the source at this quote in a new tab)
“median: NATiV3 = 7.3 | NATIVE = 6.7” (opens the source at this quote in a new tab)
“median: NATiV3 = 6.2% | NATIVE = 5.9%” (opens the source at this quote in a new tab)
“median: NATiV3 = 4.0 | NATIVE = 4.5” (opens the source at this quote in a new tab)
Liver disease characteristics of the NATiV3 main cohort compared with NATIVE, company slides
| Characteristic | NATiV3 (main cohort) | NATIVE |
|---|---|---|
| Fibrosis stage F2 | “33.0%” | “41.3%” |
| Fibrosis stage F3 | “67.0%” | “34.8%” |
| Liver stiffness measurement (kPa), median | “10.1” | “8.9” |
| Controlled attenuation parameter (dB/m), median | “329” | “327” |
| ALT (U/L), median | “50” | “51” |
| AST (U/L), median | “40” | “37” |
| FIB-4 score, median | “1.35” | “1.19” |
| ELF score, median | “9.6” | “9.7” |
“mean ±SD: NATiV3 = 324 ± 48 | NATIVE = 327.7 ± 43.2” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 59 ± 36 | NATIVE = 62 ± 39” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 47 ± 26 | NATIVE = 47 ± 32” (opens the source at this quote in a new tab)
“mean ±SD: NATiV3 = 9.7 ± 0.9 | NATIVE = 9.7 ± 1.0” (opens the source at this quote in a new tab)
Concomitant SGLT2 inhibitor and GLP-1 receptor agonist use at baseline in the NATiV3 main cohort compared with NATIVE, company slides
Interim baseline characteristics of participants randomized in the main cohort, December 2023
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, February 2024
Other milder aminotransferase elevations among trial participants, Form 20-F
Recovery of the participant with the suspected unexpected serious adverse reaction, May 2024
Third Data Monitoring Committee review of blinded safety data, December 2023
Fourth Data Monitoring Committee review of unblinded safety data, May 2024
Fifth Data Monitoring Committee review of unblinded safety data, October 2024
Study limitations
Summary: results not yet reported and blinded safety information
The ClinicalTrials.gov record gives an actual primary completion date of 2026-09-29 and an estimated study completion date of 2027-09-30. All participants had completed the 72-week treatment period, and Inventiva expected to report topline results in the fourth quarter of 2026. The safety information available comes from company statements on Data Monitoring Committee reviews: one review used safety data from more than 500 participants, including participants treated with lanifibranor for more than 72 weeks; another used unblinded data from more than 900 participants randomized in the main and exploratory cohorts; and at another the data were unblinded to the committee and remained blinded with respect to the company.
Summary: histologic surrogate endpoint, endpoint naming, and reader variability
- The primary outcome is histologic: resolution of NASH and improvement of fibrosis at week 72, defined by NASH CRN scores for ballooning of 0, inflammation of 0 to 1, and a fibrosis decrease of at least 1 stage. Inventiva states that accelerated approval and conditional authorization, even if granted, require completion of the trial to obtain full approval.
- The January 2023 protocol amendments replaced the planned Part 2 of NATiV3, a clinical outcome trial in approximately 2,000 participants with F2 and F3 fibrosis for a maximum of seven years, with a separate event-driven phase 3 outcome trial in participants with compensated cirrhosis. The Form 20-F states that the FDA's guidance during a consultation preceding the amendments was to continue NATiV3 as originally planned, and that the FDA did not object to the amendments.
- Sources name the endpoints differently. The ClinicalTrials.gov record names the composite of NASH resolution and fibrosis improvement as the primary outcome, and the investor and analyst day presentation names the composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints. The financing terms in the Form 20-F describe the two single endpoints as “key primary endpoint or key secondary endpoint”. The original registry version (April 2021) titled the primary measure "Resolution of NASH" while defining it as the composite. Efficacy for the accelerated approval of resmetirom was determined on the two single endpoints, and the EMA reflection paper states that efficacy for both endpoints (resolution of NASH and improvement of fibrosis by at least 1 stage) should be demonstrated in co-primary fashion.
- Davison et al. reported inter-reader unweighted kappas of 0.396 for NASH resolution without worsening fibrosis and 0.366 for fibrosis improvement without worsening NASH, and simulations in which unreliable endpoints and inclusion criteria reduced study power from >90% to as low as 40%.
Summary: enrollment figures, protocol amendments, and the extension period
- Enrollment figures differ by source and date. The ClinicalTrials.gov record gives an estimated enrollment of 1000 (2000 in the April 2021 version). Inventiva reports 1,009 participants in the main cohort and 410 in the exploratory cohort, exceeding the original targets of 969 and 350. The Form 20-F anticipates an NDA based on histologic endpoints in approximately 950 patients, and the NATiV3 design release planned the histology analysis in approximately 900 patients.
- The January 2023 amendments reduced the number of biopsies per participant from three to two and the trial duration a participant consents to from 7 years to 72 weeks. In 2022, recruitment was put on hold in Ukraine and all planned sites in Russia were removed.
- A treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, with biopsy results compatible with autoimmune hepatitis, led to a voluntary pause in screening and randomization, an amendment excluding newly screened patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. Before the pause, 913 participants had been randomized, including 731 in the main cohort.
- The ClinicalTrials.gov and EU Clinical Trials Information System records describe the 48-week Part B extension as double-blind; the company's last patient visit release describes it as open-label, with all participants, including those originally randomized to placebo, receiving lanifibranor.
Summary: enrolled population and generalizability
- Inventiva reported a recent screen failure rate of approximately 80% in December 2023, and the Form 20-F states that a higher than originally projected screen failure rate slowed enrollment.
- The main cohort differs from the NATIVE population in company slides: type 2 diabetes 55% versus 42%, fibrosis stage F3 67.0% versus 34.8%, obesity 75% versus 65%, GLP-1 receptor agonist use at baseline 14.0% versus 0.0%, and SGLT2 inhibitor use 10.0% versus 2.8%.
- As of December 2023, approximately 70% of participants randomized in the main and exploratory cohorts were from the United States, approximately 20% from Europe, and approximately 10% from Latin America and the rest of the world.
- Exclusion criteria include HbA1c >9% at screening, current insulin treatment, history of heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, current approved treatment for NASH or obesity, thiazolidinedione treatment in the prior 12 months, and hemoglobin <11 g/dL in females or <12 g/dL in males.
NATIVE
Objective
Purpose stated in the ClinicalTrials.gov record
Study objective in the protocol
Objective stated in the design paper
“NATIVE study (EudraCT: 2016-001979-70, NCT: NCT03008070) aims to assess the safety and the efficacy of a 24-week treatment with lanifibranor (800 and 1200 mg/day) in adult non-cirrhotic NASH patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aim of the trial in the published report
Location and study date
Study dates in the ClinicalTrials.gov record
“Study Start (Actual) 2017-02-07” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2020-02-20” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2020-03-16” (opens the source at this quote in a new tab)
“Results First Posted 2021-04-12” (opens the source at this quote in a new tab)
Registered locations
Countries and screening period in the published report
Planned sites and study period in the protocol
Study design
Phase 2b, randomized, double-blind, placebo-controlled design
Design summary in the design paper
“NATIVE is a Phase 2b randomised, placebo-controlled, double-blind, parallel-assignment, dose-range study.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Enrollment | “Enrollment (Actual) 247” |
Treatment groups, blinding, and study duration in the ClinicalTrials.gov record
Study arms, visit schedule, and selection period in the protocol
Randomization procedure in the protocol
Screening biopsy and centralized histology reading in the protocol
Rationale for the placebo comparator and the 6-month duration in the protocol
Trial oversight and sponsor role
Eligibility criteria
Key eligibility criteria in the published report
No fibrosis-stage inclusion criterion other than the exclusion of cirrhosis
“Eligible adult patients with a confirmed histological diagnosis of NASH should have a SAF Activity score of 3 or 4 (>2) and a SAF Steatosis score ≥ 1. There is no specific criterion related to the fibrosis score except that patients with cirrhosis (F4) were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Exclusion criteria in the ClinicalTrials.gov record
Laboratory criteria for compensated liver disease in the protocol
“ALT < 10xULN” (opens the source at this quote in a new tab)
“Platelets > 100 10^9/L (100 10^3/µL)” (opens the source at this quote in a new tab)
“Albumin > 36 g/L (3.6 g/dL)” (opens the source at this quote in a new tab)
“International Normalized Ratio (INR) < 1.4” (opens the source at this quote in a new tab)
Prohibited concomitant medications in the protocol
Permitted antidiabetic and lipid-lowering medications in the protocol
Treatment
Doses, schedule, and duration in the published report
Arms in the ClinicalTrials.gov record
| Arm | Description |
|---|---|
| Experimental: IVA337 1200mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Experimental: IVA337 800mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Placebo Comparator: Placebo | “Placebo to match, once a day (Quaque Die, QD) with food” |
Tablets, kits, and administration with breakfast in the protocol
“Placebo Kit: Morning (P+P+P)” (opens the source at this quote in a new tab)
“800 mg Kit: Morning (P+A+A)” (opens the source at this quote in a new tab)
“1200 mg Kit: Morning (A+A+A)” (opens the source at this quote in a new tab)
“Dosage modifications are not permitted.” (opens the source at this quote in a new tab)
Dose selection and food intake rationale in the protocol
Treatment compliance measures in the protocol
Study outcomes
Rationale for using SAF activity score decrease of at least 2 points without worsening of fibrosis as the primary endpoint
Primary end point definition in the published report
Primary outcome measure in the ClinicalTrials.gov record
Primary endpoint and responder definition in the protocol
Primary endpoint in the design paper
“The primary efficacy endpoint is a 2-point reduction in the activity part of the Steatosis Activity Fibrosis (SAF) histological score (combining inflammation and ballooning) without worsening of fibrosis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for scoring activity separately from steatosis in the published report
Justification for the SAF activity score in the protocol
Liver histology as the efficacy measure in FDA and EMA approved phase 3 trials, as stated in the protocol
Regulatory context for histologic surrogate end points in the published report
Secondary histologic and nonhistologic end points in the published report
Exploratory end points, including quality of life, in the published report
Quality-of-life questionnaires assessed in the protocol
Registered secondary end point definitions for NASH resolution and fibrosis improvement
Histology reading by one blinded pathologist
Protocol version 5.0, July 2019: secondary endpoints updated
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power in the protocol
Randomized participants and per-protocol population in the published report
Missing week 24 biopsies by group in the full analysis population
Enrollment in the ClinicalTrials.gov record
Participants analyzed at baseline in the registry results
Description of analysis sets
Full analysis, safety, and per-protocol populations in the published report
Analysis sets defined in the protocol
Primary analysis method and missing-data rule in the protocol
Multiplicity adjustment, multiple imputation, and sensitivity analyses in the published report
Analysis of continuous secondary end points in the published report
Results
Participant disposition
Screening, randomization, and completion in the published report
Participant flow and reasons for not completing in the registry results
| Milestone or reason | Lanifibranor 1200mg | Lanifibranor 800mg | Placebo |
|---|---|---|---|
| Started | “83” | “83” | “81” |
| Completed | “77” | “77” | “74” |
| Not completed | “6” | “6” | “7” |
| Adverse event | “3” | “3” | “3” |
| Lost to follow-up | “1” | “1” | “0” |
| Non compliance | “0” | “1” | “1” |
| Use of prohibited drug | “0” | “0” | “2” |
| Withdrawal by patient and adverse event non fatal | “0” | “1” | “0” |
| Withdrawal by subject | “2” | “0” | “1” |
Baseline characteristics
Baseline characteristics summarized in the published report
Demographic and clinical characteristics at baseline, full analysis population
Baseline characteristics of participants with type 2 diabetes
Selection of more severe disease through the SAF-A criterion
Antidiabetic medication, prediabetes, obesity, and statin use in the enrolled population
“Of 247 patients enrolled, 228 completed the study; mean age was 54 years, 58% were female, 94% were Caucasian, mean body mass index (BMI) was 33 kg/m2; 42% (n = 103) had T2D. Of these, 83% received metformin (alone or in combination anti-diabetic treatment), 22%, sulphonylurea; 11%, dipeptidyl peptidase-4 inhibitor; 7% sodium-glucose cotransporter-2 inhibitor medication; 13% had no antidiabetic treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 144 patients without T2D, 47 (33%) had prediabetes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 20% of patients took statins (22%, 22%, 16% with lanifibranor 1200 mg, 800 mg, and placebo respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age categories and race in the registry results
| Characteristic | IVA337 1200mg | IVA337 800mg | Placebo | Total |
|---|---|---|---|---|
| Age between 18 and 65 years | “67” | “69” | “63” | “199” |
| Age 65 years or older | “16” | “14” | “18” | “48” |
| American Indian or Alaska Native | “0” | “0” | “2” | “2” |
| Asian | “2” | “1” | “2” | “5” |
| Native Hawaiian or Other Pacific Islander | “0” | “1” | “0” | “1” |
| Black or African American | “3” | “1” | “3” | “7” |
| White | “78” | “80” | “74” | “232” |
Region of enrollment in the registry results
| Country | IVA337 1200mg | IVA337 800mg | Placebo | Total |
|---|---|---|---|---|
| Bulgaria | “17” | “16” | “22” | “55” |
| France | “15” | “15” | “9” | “39” |
| United States | “13” | “11” | “12” | “36” |
| Belgium | “10” | “11” | “11” | “32” |
| Australia | “3” | “7” | “3” | “13” |
| Germany | “7” | “3” | “3” | “13” |
| Spain | “3” | “4” | “5” | “12” |
| Czechia | “3” | “2” | “3” | “8” |
| Canada | “3” | “1” | “4” | “8” |
| United Kingdom | “3” | “2” | “2” | “7” |
| Mauritius | “2” | “3” | “2” | “7” |
| Poland | “1” | “2” | “3” | “6” |
| Italy | “3” | “1” | “1” | “5” |
| Switzerland | “0” | “3” | “1” | “4” |
| Austria | “0” | “1” | “0” | “1” |
| Slovenia | “0” | “1” | “0” | “1” |
Efficacy results
Primary endpoint: full analysis population with multiple imputation
Primary endpoint: nonresponder imputation, complete-case, per-protocol, and F2 or F3 fibrosis analyses
Key secondary histologic endpoints: multiple imputation
Histologic endpoints in participants with F2 or F3 fibrosis: journal report
Primary and key secondary histologic endpoints: ITT and per-protocol populations, company topline release
| Endpoint at week 24 | ITT placebo | ITT lanifibranor 800 mg | ITT lanifibranor 1200 mg | PP placebo | PP lanifibranor 800 mg | PP lanifibranor 1200 mg |
|---|---|---|---|---|---|---|
| Number of participants | “(N = 81)” | “(N = 83)” | “(N = 83)” | “(N = 62)” | “(N = 63)” | “(N = 69)” |
| Decrease of at least 2 points in SAF activity score (primary) | “27%” | “41% P=0.061” | “49% P=0.004*” | “34%” | “51% P=0.058” | “55% P=0.015*” |
| Resolution of NASH and no worsening of fibrosis | “19%” | “33% P=0.043*” | “45% P<0.001*” | “23%” | “40% P=0.039*” | “49% P=0.002*” |
| Improvement of fibrosis by at least one stage and no worsening of NASH | “24%” | “28% P=0.53” | “42% P=0.011*” | “29%” | “32% P=0.75” | “46% P=0.04*” |
| Resolution of NASH and improvement of fibrosis | “7%” | “21% P=0.017*” | “31% P<0.001*” | “10%” | “24% P=0.036*” | “33% P=0.001*” |
| Decrease of at least 2 points in NAS and no worsening of fibrosis | “32%” | “52% P=0.01*” | “64% P<0.001*” | “40%” | “62% P=0.02*” | “71% P<0.001*” |
Resolution of NASH without worsening of fibrosis in participants with F2 or F3 fibrosis: ITT and per-protocol populations, company topline release
| Population | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg |
|---|---|---|---|
| ITT, F2 or F3 fibrosis | “9%” | “34% P=0.011*” | “44% P<0.001*” |
| Per protocol, F2 or F3 fibrosis | “11%” | “40% P=0.016*” | “51% P<0.001*” |
Histologic endpoints: participants with a response, missing data counted as nonresponse, registry results
| Outcome measure at 24 weeks (participants with a response) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| Overall number of participants analyzed | “83” | “83” | “81” |
| SAF-A decrease of at least 2 points with no worsening of CRN-F (primary) | “41” | “34” | “22” |
| NASH improvement (NAS decrease of at least 2 points without worsening of fibrosis) | “53” | “43” | “26” |
| NASH resolution and no worsening of fibrosis | “37” | “27” | “15” |
| Improvement of fibrosis by at least 1 stage and no worsening of NASH | “35” | “23” | “19” |
| Resolution of NASH and improvement of fibrosis by at least 1 stage | “26” | “17” | “6” |
| Activity (SAF-A) improvement | “62” | “54” | “40” |
| Steatosis (CRN-S) improvement | “54” | “46” | “21” |
| Lobular inflammation (CRN-I) improvement | “43” | “34” | “30” |
| Hepatocyte ballooning (CRN-B) improvement | “60” | “54” | “37” |
| Fibrosis (CRN-F) improvement | “36” | “28” | “22” |
| Modified Ishak fibrosis (ISHAK-F) improvement | “41” | “32” | “25” |
Liver enzymes: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Alanine aminotransferase, U/liter | “−24.54 (−32.06 to −17.01)” | “−26.08 (−33.67 to −18.50)” | “−1.40 (−9.04 to 6.25)” |
| Aspartate aminotransferase, U/liter | “−12.04 (−18.29 to −5.79)” | “−15.11 (−21.43 to −8.80)” | “−0.08 (−6.43 to 6.26)” |
| γ-Glutamyltransferase, U/liter | “−27.87 (−38.88 to −16.86)” | “−43.38 (−54.46 to −32.29)” | “4.41 (−6.76 to 15.58)” |
Lipids and apolipoproteins: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Total cholesterol, mmol/liter | “−0.07 (−0.22 to 0.07)” | “−0.02 (−0.17 to 0.13)” | “0.01 (−0.14 to 0.16)” |
| Fasting HDL cholesterol, mmol/liter | “0.11 (0.06 to 0.15)” | “0.16 (0.12 to 0.21)” | “0.01 (−0.04 to 0.05)” |
| Fasting LDL cholesterol, mmol/liter | “0.03 (−0.11 to 0.16)” | “0.03 (−0.11 to 0.16)” | “0.01 (−0.12 to 0.15)” |
| Fasting triglycerides, mmol/liter | “−0.44 (−0.61 to −0.27)” | “−0.49 (−0.66 to −0.31)” | “0.06 (−0.12 to 0.23)” |
| Fasting apolipoprotein A1, mg/dl | “−4.39 (−8.64 to −0.13)” | “−0.29 (−4.61 to 4.04)” | “0.03 (−4.27 to 4.33)” |
| Fasting apolipoprotein B, mg/dl (exploratory) | “−11.61 (−15.64 to −7.57)” | “−11.51 (−15.61 to −7.41)” | “−1.85 (−5.79 to 2.09)” |
| Fasting apolipoprotein C3, μg/dl (exploratory) | “−9.98 (−17.74 to −2.22)” | “−8.08 (−16.02 to −0.13)” | “10.31 (2.67 to 17.94)” |
Glycemic markers and insulin resistance: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Fasting glucose, mmol/liter | “−0.60 (−0.83 to −0.37)” | “−0.78 (−1.01 to −0.55)” | “0.24 (0.01 to 0.47)” |
| Glycated hemoglobin, % | “−0.41 (−0.51 to −0.32)” | “−0.38 (−0.47 to −0.28)” | “0.07 (−0.02 to 0.17)” |
| Fasting insulin, pmol/liter | “−114.91 (−138.09 to −91.73)” | “−118.66 (−141.66 to −95.67)” | “−35.7 (−58.59 to −12.82)” |
| Fasting HOMA-IR index score | “−5.46 (−6.60 to −4.32)” | “−5.79 (−6.92 to −4.65)” | “−1.47 (−2.59 to −0.35)” |
Glycemic markers in participants with type 2 diabetes: journal report
Glycemic markers and adiponectin by diabetes status: mean absolute change at week 24, congress poster
| Parameter | T2DM, lanifibranor 800 mg | T2DM, lanifibranor 1200 mg | T2DM, placebo | No T2DM, lanifibranor 800 mg | No T2DM, lanifibranor 1200 mg | No T2DM, placebo |
|---|---|---|---|---|---|---|
| Fasting plasma glucose, mmol/L | “−1.71” | “−0.88” | “+0.29” | “−0.49” | “−0.39” | “+0.16” |
| HbA1c, % | “−0.60” | “−0.72” | “+0.10” | “−0.21” | “−0.25” | “+0.08” |
| HOMA index | “−10.62” | “−5.52” | “−0.60” | “−3.42” | “−7.27” | “+0.11” |
| Adiponectin, fold increase | “4.12” | “4.44” | “1.11” | “3.62” | “4.54” | “1.00” |
Adiponectin and inflammatory markers: adjusted mean change at week 24, completers in the full analysis population
| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Adiponectin, μg/ml | “17.12 (14.29 to 19.96)” | “11.95 (8.97 to 14.94)” | “−0.35 (−3.20 to 2.50)” |
| High-sensitivity CRP, mg/liter | “−1.37 (−2.28 to −0.46)” | “−2.05 (−2.97 to −1.13)” | “0.11 (−0.81 to 1.03)” |
| Fibrinogen, g/liter | “−0.10 (−0.24 to 0.05)” | “−0.17 (−0.32 to −0.02)” | “0.02 (−0.12 to 0.17)” |
| α2-Macroglobulin, g/liter | “0.13 (0.04 to 0.22)” | “0.15 (0.06 to 0.24)” | “0.05 (−0.04 to 0.13)” |
| Haptoglobin, g/liter | “−0.07 (−0.13 to 0)” | “−0.05 (−0.12 to 0.01)” | “0.05 (−0.01 to 0.12)” |
Noninvasive tests of fibrosis, apoptosis, and steatosis: completers in the full analysis population
| Change from baseline in exploratory end points (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
|---|---|---|---|
| Pro-C3, μg/liter | “−1.79 (−3.07 to −0.52)” | “−3.93 (−5.26 to −2.61)” | “−1.01 (−2.30 to 0.28)” |
| TIMP-1 to MMP-2 ratio | “−0.75 (−0.93 to −0.57)” | “−0.69 (−0.88 to −0.50)” | “−0.11 (−0.29 to 0.08)” |
| Cytokeratin 18 M30, pmol/liter | “−315.55 (−441.55 to −189.55)” | “−331.71 (−463.78 to −199.65)” | “−105.03 (−232.86 to 22.80)” |
| Enhanced Liver Fibrosis test score | “0.11 (−0.04 to 0.26)” | “−0.19 (−0.35 to −0.04)” | “−0.08 (−0.23 to 0.06)” |
| Fibrosis-4 index score | “0.03 (−0.13 to 0.19)” | “0 (−0.17 to 0.16)” | “−0.03 (−0.19 to 0.13)” |
Cardiometabolic secondary and post hoc analyses: scope and multiplicity
“This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No multiplicity adjustments were performed for the analyses presented in this paper, that are considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Limitations may include the fact that patients who meet study entry criteria may not represent all patients seen in varying practice environments; analyses were post-hoc of available data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Insulin resistance and glycemic control: adjusted mean difference versus placebo at end of treatment
“Fasting insulin levels (FIL) significantly decreased with lanifibranor in the overall population; adjusted mean difference versus placebo [AMD] at end of treatment [EOT] was −79 pmol/L (95% confidence interval [CI]: −112 to −47, p < 0.001) with lanifibranor 1200 mg; −83 pmol/L (95%CI: −115 to −51, p < 0.001) with 800 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, AMD was −0.8 mmol/L (95%CI: −1.2 to −0.5, p < 0.001) with 1200 mg and −1.0 mmol/L (95%CI: −1.4 to −0.7, p < 0.001) with 800 mg. With T2D, AMD in hemoglobin A1c (HbA1c) at EOT was −0.7% (95%CI: −1.0 to −0.4, p < 0.001) in both active arms. Overall, HbA1c was −0.5% (95%CI: −0.6 to −0.3, p < 0.001) with both lanifibranor 1200 mg and 800 mg (Table 1, Fig. 1F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Glycemic status in participants with prediabetes or normoglycemia at baseline: post hoc analysis
“With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Conversely, among 83 patients with normoglycemia at baseline, 0% with lanifibranor 1200 mg and 800 mg progressed to prediabetes at EOT, versus 26% (95%CI: 10 to 41, both p < 0.01) in the placebo arm (Supplementary Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further post-hoc analyses, i.e., not pre-specified in the SAP, included: the effects of therapy in the subgroups of patients with and without overt T2D; in patients with prediabetes at baseline” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lipids and apolipoproteins: adjusted mean difference versus placebo at end of treatment
“Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 109 patients with high baseline TG values (>1.7 mmol/L, 150.5 mg/dL), 60% and 70% on lanifibranor 1200 mg and 800 mg, respectively, improved to low-risk TG levels of ≤1.7 mmol/L at EOT, versus 27% on placebo (Supplementary Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lanifibranor significantly reduced APO-B with an AMD at EOT of −10 mg/dL (95%CI: −15 to −4, p < 0.001) with both doses (Table 1, Fig. 1D)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic inflammation and ferritin: adjusted mean difference versus placebo at end of treatment
“With lanifibranor 1200 mg and 800 mg respectively, AMD at EOT was −1.5 mg/L (95%CI: −2.8 to −0.2, p = 0.026) and −2.2 mg/L (95%CI: −3.5 to −0.9, p = 0.001)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At EOT, levels decreased significantly with lanifibranor (AMD at EOT: −84.2 µg/L [95%CI: −125.2 to –43.3], −71.8 µg/L [95%CI: −112.6 to −31.0] for lanifibranor 800 mg and 1200 mg, respectively, both p < 0.001), but were unchanged with placebo (Table 1, Fig. 1H).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blood pressure: adjusted mean difference versus placebo at end of treatment
“From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]). Systolic BP did not change significantly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hepatic steatosis by histology and controlled attenuation parameter
“Histological steatosis improved significantly at EOT with lanifibranor versus placebo, with more than 35% of patients improving by at least 2 grades with lanifibranor versus 5% with placebo (Fig. 2A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Controlled attenuation parameter (CAP™) similarly decreased significantly at EOT with lanifibranor (AMD at EOT was −23 dB/m [95%CI: −41 to −5, p = 0.012] with 1200 mg and −16 dB/m [95%CI: −33 to 1, p = 0.070] with 800 mg [Table 1]) but not with placebo (Fig. 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic and hepatic markers by weight change group: post hoc analysis
“In pooled lanifibranor arms, all CMH markers, i.e., steatosis, HOMA-IR, FIL, lipids (HDL-C, TG, APO-B, APO-C3, APO-B/APO-A), FG, hs-CRP, ferritin and DBP, as well as liver tests (ALT, AST, gamma-glutamyl transferase [GGT]), improved to the same degree in the three weight-change groups. In contrast, placebo-treated patients with increased weight at EOT had unchanged or worsening values of these markers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further post-hoc analyses, i.e., not pre-specified in the SAP, included” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“the correlation between weight changes (both continuous and by weight-change group, i.e., <2.5%, 2.5−5% and ≥5% increase from baseline) under lanifibranor and placebo, separately, and improvement in CMH markers” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adiponectin response and histologic improvement
“Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase. With placebo only 10% had moderate, and none high increase (Supplementary Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Absolute and categorical (fold change) adiponectin increase also correlated with improvement of liver histological endpoints for disease activity, i.e., CRN-NAFLD activity score (NAS) and individual activity components (ballooning and inflammation), and with improvement in fibrosis stage (38% versus 57% for adiponectin increase ≤4- versus >4-fold, respectively) (Supplementary Table 8, Fig. 5A−D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiometabolic markers in obese and non-obese participants
“Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1). Overall, the effects of lanifibranor therapy versus placebo on markers of CMH and on liver tests were similar for obese and non-obese patients (Supplementary Table 13).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adiponectin fold change at end of treatment by arm and relation to weight change: congress poster
| Fold adiponectin at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
|---|---|---|---|---|
| Number of participants | “72” | “66” | “73” | “139” |
| Mean (SD) | “1.1 ± 0.3” | “3.8 ± 3.1” | “4.5 ± 3.5” | “4.2 ± 3.3” |
| Unchanged | “65 (90%)” | “9 (14%)” | “4 (5%)” | “13 (9%)” |
| Fold 1.5 to 4 | “7 (10%)” | “38 (58%)” | “38 (52%)” | “76 (55%)” |
| Fold more than 4 | “0 (0.0%)” | “19 (29%)” | “31 (42%)” | “50 (36%)” |
Serum biomarker signatures of histologic response: pooled lanifibranor arms
“Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver sinusoidal endothelial cell capillarisation (CD34 staining) at baseline and week 24
“Among the latter, 173 patients had baseline liver tissue available for CD34 staining, including 163 with liver tissue also available at week 24.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A). Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C). Patients with lanifibranor treatment had less worsening of lobular score (placebo: 39.6%, lanifibranor 800 mg: 18.5%, lanifibranor 1,200 mg: 23.2%; p = 0.028, Fig. 5F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Histologic and metabolic response by PNPLA3 genotype: congress poster
Health-related quality of life and patient-reported outcomes
SF-36 and Flinders Fatigue Scale at week 24
Safety results
Adverse event overview: full analysis population, treatment period
| Event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| At least 1 adverse event | “62 (75)” | “59 (71)” | “50 (62)” |
| Mild | “54 (65)” | “51 (61)” | “42 (52)” |
| Moderate | “28 (34)” | “20 (24)” | “22 (27)” |
| Severe | “3 (4)” | “3 (4)” | “3 (4)” |
| Adverse event related to active drug or placebo, as assessed by the investigator | “23 (28)” | “25 (30)” | “19 (23)” |
| Adverse event that led to permanent discontinuation of the trial regimen | “3 (4)” | “4 (5)” | “3 (4)” |
| Adverse event related to active drug or placebo that led to discontinuation | “2 (2)” | “1 (1)” | “2 (2)” |
| Serious adverse event | “7 (8)” | “3 (4)” | “3 (4)” |
| Death | “0” | “0” | “0” |
| Serious adverse event related to active drug or placebo | “0” | “0” | “2 (2)” |
| Serious postprocedural condition linked to biopsy procedure | “3 (4)” | “1 (1)” | “0” |
Most frequent adverse events by arm: full analysis population
| Adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| Diarrhea | “10 (12)” | “8 (10)” | “1 (1)” |
| Fatigue | “11 (13)” | “3 (4)” | “8 (10)” |
| Nausea | “7 (8)” | “8 (10)” | “3 (4)” |
| Weight gain | “7 (8)” | “8 (10)” | “0” |
| Peripheral edema | “7 (8)” | “5 (6)” | “2 (2)” |
| Headache | “7 (8)” | “4 (5)” | “4 (5)” |
| Abdominal pain | “5 (6)” | “4 (5)” | “4 (5)” |
| Dizziness | “6 (7)” | “2 (2)” | “3 (4)” |
| Anemia | “6 (7)” | “1 (1)” | “0” |
| Constipation | “5 (6)” | “3 (4)” | “6 (7)” |
| Increase in aminotransferase level | “3 (4)” | “5 (6)” | “1 (1)” |
Serious adverse events by arm: full analysis population
| Other serious adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
|---|---|---|---|
| Wrist fracture | “0” | “0” | “1 (1)” |
| Unstable angina | “1 (1)” | “0” | “0” |
| Heart failure | “0” | “0” | “1 (1)” |
| Gastroenteritis | “1 (1)” | “0” | “0” |
| Pyelonephritis | “1 (1)” | “0” | “0” |
| Pancreatitis | “0” | “1 (1)” | “0” |
| Undifferentiated connective tissue disease | “0” | “1 (1)” | “0” |
| Urticaria | “0” | “0” | “1 (1)” |
| Foot operation | “1 (1)” | “0” | “0” |
Discontinuations and severe adverse events
Peripheral edema: character, management, and sex of participants with drug-related cases, company presentation
Body weight: mean change from baseline at week 24
Body weight: distribution of weight change at end of treatment, pooled lanifibranor arms
“patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Weight change showed considerable interindividual variability: at EOT, 51% of patients in pooled lanifibranor arms had stable weight (≤2.5% increase), 16% had moderate increase (2.5−5%), and 33% had ≥5% increase from baseline; with placebo 84% had stable weight, but 16% had >2.5% weight increase (Supplementary Fig. 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Body weight: weight change category at week 24 by arm, completers, congress poster
| Weight at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
|---|---|---|---|---|
| Number of participants | “73” | “71” | “73” | “144” |
| Stable (2.5% or less) | “61 (84%)” | “41 (58%)” | “32 (44%)” | “73 (51%)” |
| Increase (more than 2.5%), placebo only | “12 (16%)” | “–” | “–” | “–” |
| Increase (2.5% to 5%) | “–” | “9 (13%)” | “14 (19%)” | “23 (16%)” |
| Increase (more than 5%) | “–” | “21 (30%)” | “27 (37%)” | “48 (33%)” |
Anemia and hemoglobin
Heart failure and NT-proBNP
“N-terminal pro b-type natriuretic peptide (NT-proBNP) increased with both lanifibranor doses; AMD at EOT was 8.4 pmol/L (71 pg/mL) with lanifibranor 1200 mg and 4.0 pmol/L (34 pg/mL) with 800 mg (Table 1, Fig. 1J), this increase being correlated with weight increase (Supplementary Table 4, Fig. 3G).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious adverse events: registry results
| Serious adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/83 (0.00%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Total serious adverse events | “7/83 (8.43%)” | “3/83 (3.61%)” | “3/81 (3.70%)” |
| Angina unstable | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Cardiac failure | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Pancreatitis | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Pneumobilia | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Gastroenteritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Pyelonephritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Post procedural haematoma | “2/83 (2.41%)” | “1/83 (1.20%)” | “1/81 (1.23%)” |
| Post procedural haemorrhage | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Procedural pain | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Wrist fracture | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Undifferentiated connective tissue disease | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Urticaria | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Foot operation | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
Other adverse events at the 5% reporting threshold: registry results
| Other adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
|---|---|---|---|
| Total | “60/83 (72.29%)” | “48/83 (57.83%)” | “30/81 (37.04%)” |
| Diarrhoea | “10/83 (12.05%)” | “8/83 (9.64%)” | “1/81 (1.23%)” |
| Nausea | “7/83 (8.43%)” | “8/83 (9.64%)” | “3/81 (3.70%)” |
| Constipation | “5/83 (6.02%)” | “3/83 (3.61%)” | “6/81 (7.41%)” |
| Fatigue | “11/83 (13.25%)” | “3/83 (3.61%)” | “8/81 (9.88%)” |
| Oedema peripheral | “7/83 (8.43%)” | “5/83 (6.02%)” | “2/81 (2.47%)” |
| Viral upper respiratory tract infection | “3/83 (3.61%)” | “3/83 (3.61%)” | “5/81 (6.17%)” |
| Weight increased | “7/83 (8.43%)” | “8/83 (9.64%)” | “0/81 (0.00%)” |
| Transaminases increased | “3/83 (3.61%)” | “5/83 (6.02%)” | “1/81 (1.23%)” |
| Headache | “7/83 (8.43%)” | “4/83 (4.82%)” | “4/81 (4.94%)” |
| Dizziness | “6/83 (7.23%)” | “2/83 (2.41%)” | “3/81 (3.70%)” |
Study limitations
Summary: duration, sample size, histology reading, and sponsor role
- Treatment lasted 24 weeks; the protocol states that 6 months is sufficient in a proof-of-concept study and limits the time on placebo.
- The protocol planned 225 randomized participants (75 per arm) for at least 80% power with a two-sided alpha of 0.025, assuming a placebo responder rate of 10% and an excess responder rate of 20%. The placebo response on the primary endpoint was 33% in the multiple imputation analysis of the journal report and 27% in the intention-to-treat population of the company topline release. A total of 247 participants were randomized (83, 83, and 81) out of 868 screened.
- All biopsy samples were read by one pathologist who was unaware of timing and group assignment.
- No fibrosis-stage inclusion criterion was set other than exclusion of cirrhosis; 188 participants (76%) had stage F2 or F3 fibrosis, and results in this group come from a subgroup analysis.
- The journal report states that the validity of the SAF-A score as a surrogate for long-term outcomes “warrants further study”, and that changes in noninvasive biomarkers should be interpreted with caution, “particularly in short-term trials”.
- The sponsor designed the trial, monitored the sites, collected the data, and analyzed the data.
Summary: missing biopsies, analysis methods, protocol changes, and figures that differ by source
- Week 24 biopsies were missing for 34 participants (11 at 800 mg, 9 at 1200 mg, and 14 with placebo). The protocol specified that an amendment would be submitted to increase the sample size if end-of-study slides were unavailable or uninterpretable in more than 5% of participants.
- The protocol's primary rule counted missing data as nonresponse; the journal report's primary analysis used multiple imputation. With multiple imputation, the primary endpoint was met by 55% with 1200 mg and 48% with 800 mg versus 33% with placebo (P=0.007 and P=0.07). The company topline release (intention-to-treat, all randomized) gives 49% (P=0.004) and 41% (P=0.061) versus 27%, and the registry, counting missing data as nonresponse, gives 41 of 83, 34 of 83, and 22 of 81 responders. The journal report states that nonresponder imputation and complete-case results were similar.
- No multiplicity adjustments were defined for secondary and exploratory end points. The cardiometabolic analyses of Cooreman et al. had no multiplicity adjustment, are considered exploratory, and include post hoc analyses.
- Protocol version 5.0, dated July 9, 2019, updated the secondary endpoints. The registry states that the last participant was recruited in March 2019, and the journal report gives a screening period of February 2017 through July 2019.
- The selection period is 3 days to 4 weeks in the protocol and 10 days to 4 weeks in the registry.
- Discontinuations for adverse events are 3 (4%), 4 (5%), and 3 (4%) in the journal report (1200 mg, 800 mg, placebo) and 3, 3, and 3 in the registry participant flow, which lists one further 800 mg participant under “Withdrawal by patient and adverse event non fatal”.
Summary: enrolled population and generalizability
- Of 247 participants, 232 (94%) were White and 103 (42%) had type 2 diabetes. By registry region of enrollment, 55 were enrolled in Bulgaria, 39 in France, and 36 in the United States.
- The protocol required GLP-1 receptor agonists, vitamin E, fibrates, and PPAR gamma agonists to be stopped before randomization, and the registry excluded participants with type 2 diabetes on insulin, HbA1c >8.5%, or body mass index >45 kg/m2.
- Cooreman et al. state that participants who meet study entry criteria may not represent all patients seen in varying practice environments.
LEGEND
Objective
Purpose stated in the ClinicalTrials.gov brief summary
Primary and secondary objectives in the statistical analysis plan
Objectives in the protocol: confirming the NATIVE glycemic effect and testing the empagliflozin combination
Rationale in the protocol for combining lanifibranor with an SGLT2 inhibitor
Proof-of-concept purpose and plans for the combination stated in the annual report
Location and study date
Registered locations
Planned sites in the protocol synopsis
Recruitment period, screening, and results posting in the ClinicalTrials.gov results
Interim analysis data cut-off and date in the statistical analysis plan
Study design
Three-arm design with an open-label combination arm in the protocol
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “39” |
Stratified randomization and sex quotas in the protocol
Rationale in the protocol for blinding the lanifibranor and placebo arms only
Interim analysis and stopping of recruitment
Treatment and follow-up periods in the poster
Eligibility criteria
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record: cirrhosis, prior therapies, and BMI
Diagnosis of MASH by historical histology or noninvasive methods
Imaging definitions of NASH and the glycemic criterion in the protocol
Cirrhosis exclusion by biopsy or noninvasive criteria in the protocol
Other exclusion criteria in the protocol: weight change, NT-proBNP, renal function, and CYP2C8 interacting drugs
Autoimmune liver and thyroid disease exclusion following NATiV3 Data Monitoring Committee recommendations
Key inclusion criteria in the poster
Treatment
Treatment arms in the ClinicalTrials.gov record
Investigational treatments, dose adjustment, and interruption rules in the protocol
Background antidiabetic therapy, prohibited medications, and rescue medication in the protocol
Study outcomes
Rationale for using change in HbA1c as the primary endpoint
Primary endpoint as registered
Rationale: confirming the HbA1c decrease seen in NATIVE participants with type 2 diabetes
Rationale: shared metabolic pathways of NASH and type 2 diabetes
Secondary endpoints in the protocol: liver tests, glycemic response, body weight, and body composition
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size and power calculation in the protocol
Treated participants in the full analysis set and participants in the primary MMRM analysis (registry)
Participants in the interim analysis
Description of analysis sets
Analysis sets defined in the statistical analysis plan
Hierarchical testing, type I error, and multiplicity in the protocol
Mixed model for repeated measures for the primary endpoint in the registry
Handling of intercurrent events in the poster
Results
Participant disposition
Participant flow by arm in the ClinicalTrials.gov results
“Started 12 13 14” (opens the source at this quote in a new tab)
“Completed 12 12 9” (opens the source at this quote in a new tab)
“Not Completed 0 1 5” (opens the source at this quote in a new tab)
“Adverse Event 0 1 0” (opens the source at this quote in a new tab)
“Lost to Follow-up 0 0 2” (opens the source at this quote in a new tab)
“Non compliance with study drug 0 0 1” (opens the source at this quote in a new tab)
“Withdrawal by Subject 0 0 2” (opens the source at this quote in a new tab)
Screening and reasons for non-randomization in the ClinicalTrials.gov results
Disposition by arm in the poster
Baseline characteristics
Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table
| Characteristic | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo | Total |
|---|---|---|---|---|
| Participants | “12 participants” | “13 participants” | “14 participants” | “39 participants” |
| Age, years, mean (SD) | “55.1(11.45)” | “54.2(13.48)” | “54.7(13.01)” | “54.6(12.38)” |
| Female, n | “6” | “8” | “7” | “21” |
| White, n | “10” | “10” | “9” | “29” |
| Hispanic or Latino, n | “7” | “4” | “7” | “18” |
| HbA1c ≥7.5%, n | “8” | “8” | “9” | “25” |
| Weight, kg, mean (SD) | “93.30(11.614)” | “103.30(12.437)” | “94.50(21.269)” | “97.06(16.213)” |
| BMI, kg/m2, mean (SD) | “33.34(2.282)” | “37.62(4.300)” | “34.54(5.442)” | “35.19(4.554)” |
Median baseline characteristics in the poster
| Characteristic | Lanifibranor | Lanifibranor plus empagliflozin | Placebo | Total |
|---|---|---|---|---|
| Age (years) | “55.5” | “54.0” | “55.5” | “55.0” |
| Sex (% female) | “6 (50)” | “8 (62)” | “7 (50)” | “21 (54)” |
| Country (% USA) | “11 (92)” | “12 (92)” | “12 (86)” | “35 (90)” |
| Weight (kg) | “93.9” | “99.9” | “97.4” | “97.2” |
| HbA1c (%) | “7.7” | “8.0” | “7.50” | “7.7” |
| ALT (U/L) | “53.0” | “52.0” | “33.0” | “39.0” |
| HOMA-IR | “9.4” | “10.9” | “16.3” | “10.8” |
| cT1 (ms) | “938” | “926” | “942” | “931” |
| MRI-PDFF (%) | “18.6” | “21.1” | “20.3” | “19.3” |
Efficacy results
Primary endpoint: absolute change in HbA1c from baseline to week 24, MMRM analysis (registry)
| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| Participants analyzed | “11” | “13” | “13” |
| LS mean (95% CI) | “-1.11 (-1.6 to -0.62)” | “-1.54 (-2.02 to -1.06)” | “0.16 (-0.32 to 0.63)” |
Primary endpoint and HbA1c responders, FAS (poster)
HbA1c reduction and responders (company release, November 2024)
Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)
| Interim analysis measure | Placebo | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg |
|---|---|---|---|
| HbA1c, LS mean absolute change from baseline to week 24 (%), FAS | “0.26” | “-1.14” | “-1.59” |
| Participants, FAS | “(n=9)” | “(n=11)” | “(n=10)” |
| HbA1c <6.5% at week 24 (%), completers | “0” | “55” | “63” |
| HbA1c absolute decrease ≥1% at week 24 (%), completers | “0” | “64” | “88” |
Hepatic steatosis by MRI-PDFF and cT1, LS mean change at week 24, FAS (poster)
Hepatic steatosis by MRI-PDFF at the interim analysis (company release, March 2024)
Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)
| Outcome (unit) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| ALT, absolute change (U/L) | “-26.60 (-38.08 to -15.12)” | “-29.63 (-42.13 to -17.13)” | “-5.65 (-17.89 to 6.59)” |
| AST, absolute change (U/L) | “-13.67 (-20.66 to -6.68)” | “-17.81 (-25.5 to -10.12)” | “1.3 (-6.11 to 8.71)” |
| HOMA-IR, percentage change | “-50.79 (-95.69 to -5.89)” | “-45.23 (-89.86 to -0.61)” | “35.01 (-10.29 to 80.32)” |
| Insulin, percentage change | “-33.48 (-68.24 to 1.28)” | “-38.16 (-72.16 to -4.16)” | “10.17 (-23.63 to 43.96)” |
| Adiponectin, fold change | “2.87 (2.05 to 3.68)” | “3.03 (2.18 to 3.89)” | “1.24 (0.39 to 2.09)” |
| HDL cholesterol, relative change (%) | “16.48 (5.24 to 27.72)” | “15.30 (3.04 to 27.56)” | “2.55 (-9.76 to 14.86)” |
| VAT/SAT ratio, relative change (%) | “-4.6 (-14.44 to 5.25)” | “-17.45 (-28.67 to -6.23)” | “2.01 (-9.12 to 13.14)” |
Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)
| LS mean at week 24 (p value versus placebo) | Lanifibranor | Lanifibranor plus empagliflozin | Placebo |
|---|---|---|---|
| GGT absolute change (IU/L) | “-21.9 (0.010)” | “-17.8 (0.015)” | “22.8” |
| TIMP-1 absolute change (ng/mL) | “-42.8 (0.040)” | “-40.0 (0.056)” | “-6.8” |
| Pro-C3 absolute change (ng/mL) | “-1.26 (0.120)” | “-3.54 (0.062)” | “7.33” |
| hs-CRP relative change (%) | “-32 (0.024)” | “-48 (0.008)” | “34” |
| Ferritin absolute change (µg/L) | “-78 (0.002)” | “-59 (0.022)” | “-8” |
| Glucose absolute change (mmol/L) | “-2.36 (0.005)” | “-1.98 (0.022)” | “-0.23” |
| Triglycerides relative change (%) | “-26 (0.006)” | “-27 (0.005)” | “-2” |
Visceral to subcutaneous adipose tissue ratio and spleen volume, final analysis (poster) and interim analysis (company release)
Comparable effects of lanifibranor alone and with empagliflozin
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Body weight, relative change from baseline to week 24, LS mean (95% CI) (registry)
| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| Body weight, relative change (%) | “3.6 (2 to 5.19)” | “0.25 (-1.50 to 2.01)” | “-1.16 (-2.84 to 0.53)” |
Body weight with lanifibranor alone and with empagliflozin (poster and company release)
Mortality, serious adverse events, and selected other adverse events by arm (registry)
| Event, affected / at risk (%) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
|---|---|---|---|
| All-cause mortality | “0/12 (0.00%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Other (not including serious) adverse events, total | “10/12 (83.33%)” | “9/13 (69.23%)” | “8/14 (57.14%)” |
| Serious adverse event: haematuria | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Anemia | “2/12 (16.67%)” | “0/13 (0.00%)” | “1/14 (7.14%)” |
| Oedema peripheral | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Headache | “2/12 (16.67%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Nausea | “1/12 (8.33%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Alopecia | “2/12 (16.67%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Diabetes mellitus inadequate control | “0/12 (0.00%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Blood glucose decreased | “0/12 (0.00%)” | “1/13 (7.69%)” | “1/14 (7.14%)” |
Tolerability statements by the company
Study limitations
Summary: sample size, early stop of recruitment, open-label arm, and multiplicity
- The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
- The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
- Treatment lasted 24 weeks, followed by a 4-week follow-up.
- No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
- Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.
Summary: population, endpoints, missing data, and figures that differ by source
- MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
- The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
- In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
- The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.
NCT03459079
Objective
Aim stated in the published report
Location and study date
Study dates and location in the ClinicalTrials.gov record
“Study Start (Actual) 2018-08-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2023-04-18” (opens the source at this quote in a new tab)
“Study Completion (Actual) 2023-06-01” (opens the source at this quote in a new tab)
“This study has 1 location” (opens the source at this quote in a new tab)
“Gainesville, Florida, United States, 32610” (opens the source at this quote in a new tab)
Results posting date in the ClinicalTrials.gov results
Site, recruitment sources, and enrollment period in the published report
Study design
Single-center, double-blind, placebo-controlled design in the published report
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “A two arm randomized (1:1), double-blind, placebo-controlled, trial.” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Phase | “Phase 2” |
Run-in, treatment, and follow-up periods in the ClinicalTrials.gov record
Visits and end-of-treatment assessments in the published report
Healthy control group for metabolic and imaging reference values
Funding by Inventiva and role of the funder
Eligibility criteria
Key inclusion and exclusion criteria in the published report
Key inclusion criteria in the ClinicalTrials.gov record
Key exclusion criteria in the ClinicalTrials.gov record: other liver disease, alcohol, insulin or pioglitazone, CYP2C8 interacting drugs, and BMI
Population not selected for fibrosis stage F2 or higher
Treatment
Lanifibranor and placebo tablets in the ClinicalTrials.gov record
Dose, administration with food, dose selection, and comparator in the protocol
Background antidiabetic therapy and run-in titration in the ClinicalTrials.gov record
Study outcomes
Rationale for using intrahepatic triglyceride content by proton magnetic resonance spectroscopy as the primary endpoint
Primary endpoint as registered
Primary endpoint in the protocol and the published report
Proton magnetic resonance spectroscopy as the reference imaging method
Thresholds for liver fat response and resolution and their assumed relation to histology in the protocol
Relation of steatosis to insulin resistance and to histological response in the published report
Secondary endpoints: insulin sensitivity by clamp, IHTG response, cardiometabolic parameters, and liver stiffness
Statistical analysis description
Number of participants (Planned and analyzed)
Planned sample size revised on the basis of NATIVE steatosis results in the protocol
Reduction of the planned number of participants stated in the ClinicalTrials.gov results
Registry actual enrollment of 128 and 38 randomized participants
Randomized participants, full analysis set, and completers in the published report and the poster
Randomized participants in the company topline release
Description of analysis sets
Analysis sets defined in the protocol
Analysis sets, statistical tests, multiplicity, and missing data in the published report
Results
Participant disposition
Participant flow by group in the ClinicalTrials.gov results
“Started 20 18 10” (opens the source at this quote in a new tab)
“Completed 14 14 10” (opens the source at this quote in a new tab)
“Not Completed 6 4 0” (opens the source at this quote in a new tab)
“Adverse Event 4 2 0” (opens the source at this quote in a new tab)
“Withdrawal by Subject 2 2 0” (opens the source at this quote in a new tab)
Completion and reasons for discontinuation in the published report
Baseline characteristics
Baseline clinical and laboratory characteristics, FAS (published report)
| Characteristic | Placebo (n = 18) | Lanifibranor (n = 20) |
|---|---|---|
| Age, years (mean ± SD) | “58 ± 11” | “61 ± 7” |
| Gender (% male/female) | “28/72” | “45/55” |
| White, n (%) | “15 (83%)” | “18 (90%)” |
| Weight, kg (mean ± SD) | “99 ± 20” | “96 ± 14” |
| Body mass index, kg/m2 (mean ± SD) | “34.3 ± 6.2” | “33.8 ± 5.1” |
| Fasting plasma glucose, mg/dl (mean ± SD) | “122 ± 22” | “130 ± 26” |
| HbA1c, % (mean ± SD) | “7.0 ± 0.8” | “6.8 ± 0.5” |
| Fasting plasma insulin, μU/ml (mean ± SD) | “18.2 ± 12.7” | “16.4 ± 8.6” |
| Triglycerides, mg/dl (mean ± SD) | “196 ± 101” | “175 ± 95” |
| HDL-C, mg/dl (mean ± SD) | “43 ± 12” | “42 ± 9” |
| Alanine aminotransferase, U/L (mean ± SD) | “35 ± 27” | “37 ± 20” |
| Aspartate aminotransferase, U/L (mean ± SD) | “31 ± 19” | “31 ± 14” |
| HOMA-IR (mean ± SD) | “5.4 ± 3.4” | “5.6 ± 3.2” |
| Adiponectin, μg/ml (mean ± SD) | “5.0 ± 3.7” | “4.5 ± 2.8” |
| Intrahepatic triglyceride content, % (mean ± SD) | “18 ± 7” | “21 ± 7” |
| Liver stiffness by MRE, kPa (mean ± SD) | “2.5 ± 1.1” | “2.8 ± 0.8” |
Mean baseline HbA1c stated in the discussion of the published report
Baseline cT1, CAP, and LSM (poster)
| Characteristic | Lanifibranor (N=20) | Placebo (N=18) |
|---|---|---|
| Baseline corrected T1 mapping, ms | “887 ± 72” | “924 ± 116” |
| Baseline CAP, db/m | “356 ± 36” | “352 ± 28” |
| Baseline LSM, kPa | “8.3 ± 4.6” | “8.2 ± 7.2” |
Efficacy results
Primary endpoint: absolute change in IHTG at week 24, FAS and completers (published report)
Relative change in IHTG, IHTG reduction of at least 30%, and steatosis resolution, FAS and completers (published report)
IHTG endpoints at week 24 (registry)
| Outcome | Lanifibranor (n = 20) | Placebo (n = 18) |
|---|---|---|
| Absolute change in IHTG, LS mean (95% CI) | “-8.7 (-11.3 to -6.0)” | “-3.0 (-5.9 to -0.2)” |
| IHTG decrease of ≥30%, % of participants (95% CI) | “65 (41 to 85)” | “22 (6 to 48)” |
| NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI) | “25 (9 to 49)” | “0 (0 to 19)” |
Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)
Hepatic glucose production and muscle glucose disposal, completers (published report)
Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)
| Outcome | Lanifibranor | Placebo |
|---|---|---|
| Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18 | “-1.49 (-2.66 to -0.31)” | “-0.34 (-1.57 to 0.9)” |
| Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18 | “0.23 (0.03 to 0.42)” | “-0.06 (-0.25 to 0.13)” |
| Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18 | “-130.71(164.28)” | “-70.21(230.39)” |
Primary endpoint as reported in the 2023 congress poster, FAS and completers
Topline results, FAS and completers (company release, June 2023)
“Full Analysis Set (N=38)” (opens the source at this quote in a new tab)
“Completers (N=28)” (opens the source at this quote in a new tab)
“June 13, 2023” (opens the source at this quote in a new tab)
| Completers, change from baseline to week 24 | Placebo (n=14) | Lanifibranor 800 mg (n=14) |
|---|---|---|
| Absolute change in HbA1c, % | “-0.2%” | “-0.9” |
| Absolute change in fasting plasma insulin, μU/ml | “-1.0” | “-6.7” |
| Absolute change in hepatic insulin resistance index | “-9.5” | “-30.1” |
| Absolute change in basal endogenous glucose production (mg/kgLBM/min) | “0.1” | “-0.5” |
| Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min) | “-0.2” | “+2.2” |
| Absolute change in HDL-C, mg/dl | “-0.3” | “6.3” |
| Absolute change in adiponectin, μg/mL | “-0.2” | “7.5” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Weight gain, adverse events, and discontinuations (published report)
Treatment-emergent adverse events by group (published report)
| Event, n (%) | Placebo (n = 18) | Lanifibranor (n = 20) |
|---|---|---|
| Patients with TEAEs | “17 (94%)” | “18 (90%)” |
| Patients with severe TEAEs | “0 (0%)” | “1 (5%)” |
| Patients with serious adverse events | “0 (0%)” | “1 (5)” |
| TEAEs leading to drug discontinuation | “2 (11%)” | “4 (20%)” |
| Drug-related TEAE leading to discontinuation | “2 (11%)” | “3 (15%)” |
| Diarrhea | “3 (17%)” | “5 (25%)” |
| Elevated lipase level | “3 (17%)” | “5 (25%)” |
| Anemia | “2 (11%)” | “4 (20%)” |
| Leukopenia | “1 (6%)” | “3 (15%)” |
| Headache | “1 (6%)” | “3 (15%)” |
| Arthralgia | “3 (17%)” | “0 (0%)” |
| Oedema | “0 (0%)” | “1 (5%)” |
| Hypoglycemia | “0 (0%)” | “1 (5%)” |
| Decrease in eGFR | “2 (11%)” | “1 (5%)” |
Weight change in kilograms, edema, hemoglobin, and lipase (poster)
Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)
| Event, affected / at risk (%) | Lanifibranor | Placebo |
|---|---|---|
| All-cause mortality | “0/20 (0.00%)” | “0/18 (0.00%)” |
| Serious adverse events, total | “1/20 (5.00%)” | “0/18 (0.00%)” |
| Other (not including serious) adverse events, total | “18/20 (90.00%)” | “17/18 (94.44%)” |
| Anaemia | “4/20 (20.00%)” | “2/18 (11.11%)” |
| Diarrhoea | “5/19 (26.32%)” | “3/18 (16.67%)” |
| Elevated lipase level | “5/20 (25.00%)” | “3/18 (16.67%)” |
| Edema | “1/20 (5.00%)” | “0/18 (0.00%)” |
Study limitations
Summary: design, sample size, and enrolled population
- The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
- The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
- The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
- The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
- The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.
Summary: missing-data handling, multiplicity, and figures that differ by source
- For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
- The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
- The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).